Literature DB >> 17265445

Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.

Carsten Denkert1, Andrea Thoma, Silvia Niesporek, Wilko Weichert, Ines Koch, Aurelia Noske, Hanka Schicktanz, Mick Burkhardt, Klaus Jung, Manfred Dietel, Glen Kristiansen.   

Abstract

BACKGROUND: Cyclooxygenases (COX) as well as Polo-like kinases (PLK) are involved in proliferation and cell cycle regulation and have been suggested for preventive and therapeutic approaches in prostate carcinoma.
METHODS: In this study, we studied expression and prognostic impact of COX-2 in invasive prostate carcinoma, prostatic intraepithelial neoplasia (PIN), atrophic glands, and normal prostatic glands, and investigated the association between COX-2 and PLK-1.
RESULTS: We observed a positivity for COX-2 in 72.1% of PIN and in 44.7% of prostate carcinomas with an overexpression of COX-2 in prostate cancer and PIN compared to benign prostatic tissue (P < 0.0005). Furthermore, we observed a strong correlation between expression of PLK-1 and COX-2 (P < 0.0005).
CONCLUSIONS: To our knowledge, this is the first report of a correlation between COX-2 and PLK-1 in a malignant tumor. COX-2 and PLK-1 may be interesting targets for new molecular therapies in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17265445     DOI: 10.1002/pros.20467

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Role of senescence and mitotic catastrophe in cancer therapy.

Authors:  Richa Singh; Jasmine George; Yogeshwer Shukla
Journal:  Cell Div       Date:  2010-01-21       Impact factor: 5.130

Review 2.  Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer.

Authors:  Ning Shao; Ninghan Feng; Yang Wang; Yuanyuan Mi; Tian Li; LiXin Hua
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

3.  p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Anna Patrikidou; Ioannis A Voutsadakis; Grigorios Kakkas; George Moutzouris; Elias Zintzaras; Danai D Daliani; Michael D Melekos; Christos N Papandreou
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

4.  Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.

Authors:  Safia Salaria; Anna Means; Frank Revetta; Kamran Idrees; Eric Liu; Chanjuan Shi
Journal:  Am J Clin Pathol       Date:  2015-10       Impact factor: 2.493

5.  Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.

Authors:  Jay H Fowke; Saundra S Motley; Joseph A Smith; Michael S Cookson; Raoul Concepcion; Sam S Chang; Susan Byerly
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

6.  Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer?

Authors:  Byung Hoon Kim; Chun Il Kim; Hyuk Soo Chang; Mi Sun Choe; Hye Ra Jung; Duk Yoon Kim; Choal Hee Park
Journal:  Korean J Urol       Date:  2011-04-22

Review 7.  Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Hongtuan Zhang; Yong Xu; Zhihong Zhang; Ranlu Liu; Baojie Ma
Journal:  BMC Immunol       Date:  2012-03-21       Impact factor: 3.615

8.  Effects of tumour necrosis factor α upon the metabolism of the endocannabinoid anandamide in prostate cancer cells.

Authors:  Jessica Karlsson; Sandra Gouveia-Figueira; Mireille Alhouayek; Christopher J Fowler
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

9.  COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Priti Lal; Michael D Feldman; Emer M Smyth; Emanuela Ricciotti; Tilo Grosser; Fernando Benavides; Marcelo G Kazanietz
Journal:  Oncogene       Date:  2018-05-16       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.